Project Grant R34HL179910
Award Date 9/15/25
Completion Date 8/31/28
Dollars Obligated $233K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
- This $775,992 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells and glucocorticoids in the resolution of acute lung injury and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through regulatory T cells impacts the recovery of lung structure and function following...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate how early-life inflammation and viral infections shape the development and function of type 2 innate lymphoid cells (ILC2s) in the lungs, and their role in driving childhood asthma susceptibility. The $740,709 award to the University of Utah is intended to define the cellular and molecular mechanisms by...
- This $2,456,717 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to exploit emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma. The award supports a highly collaborative research team at Thomas Jefferson University's Sidney Kimmel Medical College to pursue three key goals: 1) identify novel targets and targeting molecules involving G protein-coupled receptor...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $760,759 to the University of Illinois to examine the immunoregulatory role of a specific dendritic cell subset, CX3CR1+CDC2, in allergic lung inflammation. The project aims to characterize the anti-inflammatory functions of this cell population and its impact on regulatory T cell development and the resolution of allergic asthma symptoms. Through the use of novel...
- This federal Project Grant award, valued at $801,648.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The grant aims to uncover the molecular mechanisms responsible for the protective effects of early endotoxin exposure against asthma. The key objectives are to investigate the role of the MIZ1 protein in mediating the protective effects of endotoxin against allergic asthma, determine the...
- The University of New Mexico was awarded a $522,990 Project Grant under the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837). The grant, awarded on September 1, 2025, will support research to elucidate the mechanisms underlying the counter-regulation of allergic airway inflammation by regulating the responsiveness of Group 2 Innate Lymphoid Cells (ILC2s). The proposed studies aim to address the knowledge gap in...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...
- This $680,562 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the long-term lung epithelial alterations resulting from early-life respiratory syncytial virus (RSV) infection. The research aims to determine the mechanisms by which early-life RSV infection predisposes individuals to developing asthma later in life, focusing on the role of innate cytokines like IL-1β and IL-33 in driving...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $189,000 Project Grant under CFDA #93.837 Cardiovascular Diseases Research program to the University of Colorado-Denver. The 2-year grant, with a period of performance from September 15, 2025 to August 31, 2027, will support research to investigate the role of outdoor air pollution and environmental allergens in driving treatment response in children with acute asthma...